Silent artery plaques found in many adults under 30

Large screening study finds early artery disease is far more common than many assumed

Atherosclerosis is usually discussed as a disease of middle and older age, surfacing only after a heart attack, a stroke, or years of elevated risk factors. New findings presented on August 29, 2026 at ESC Congress 2026 suggest that timeline is often wrong. In a large international study of apparently healthy adults with no prior cardiovascular diagnosis, researchers found that silent atherosclerotic plaques were already present across adulthood, including in a meaningful share of people younger than 30.

The study, called REACT, included more than 16,000 participants and was described by its organizers as one of the largest efforts so far to map hidden atherosclerosis throughout adult life. According to the results, 57.1% of participants had atherosclerotic plaques despite having no symptoms and no previous diagnosis of cardiovascular disease. The finding matters because atherosclerosis is the process underlying most cardiovascular disease, even when it remains clinically silent for years or decades.

The headline figure is striking, but the age detail may be even more unsettling. The study indicates that silent artery plaques may appear in about one in 13 adults before age 30. That pushes the conversation on prevention into much earlier life stages than standard public understanding often allows. Instead of imagining cardiovascular disease as something that begins when symptoms arrive, the REACT data reinforce a different picture: damage can start accumulating long before the healthcare system or the patient recognizes a problem.

A prevention model aimed at finding disease earlier

The REACT program is a collaboration involving Rigshospitalet and other Danish hospitals together with Spain’s Centro Nacional de Investigaciones Cardiovasculares Carlos III, or CNIC. The study was led by Professor Henning Bundgaard of Rigshospitalet in Copenhagen and Dr. Borja Ibanez, scientific director of CNIC, a cardiologist at Hospital Universitario Fundacion Jimenez Diaz, and a group leader at CIBERCV.

Bundgaard said the vision of REACT is to transform primary cardiovascular prevention through a precision medicine approach based on the early identification of atherosclerosis. That framing is important. Much of current prevention still relies on estimating the probability that a person will later develop disease based on age, cholesterol, blood pressure, smoking, family history, and similar indicators. REACT instead begins from the premise that directly identifying whether atherosclerosis is already present could change how prevention is targeted.

Ibanez described the study as based on a simple but revolutionary idea: shifting away from a model that estimates future probability and toward one that identifies existing disease earlier. Even without the full methodological details in the source text, the implication is clear. If clinicians can detect plaques before symptoms appear, prevention may become more individualized, and perhaps more urgent, for people who would otherwise be considered relatively low risk.

Why hidden plaque matters even before symptoms

Atherosclerosis is the main cause of cardiovascular disease and typically shows up later as heart attacks, strokes, or sudden death. Not every person with plaques will go on to develop symptomatic disease, but the scale of the problem is enormous. The source text notes that nearly 20 million people worldwide die from cardiovascular disease every year, with most of those deaths caused by atherosclerosis.

That burden helps explain why early detection is such an attractive goal. A disease process that remains quiet for decades can still be progressing throughout those decades. By the time symptoms emerge, the underlying arterial changes are often well established. REACT therefore adds weight to an argument that prevention should not start only when traditional risk becomes obvious or when clinical events force action.

The new data do not mean that half the adult population is on the verge of a cardiac emergency. They do mean, however, that silent arterial disease appears to be much more prevalent than previously thought, including among people who look healthy by conventional standards. That distinction matters for how the public interprets the findings. Hidden plaque is not the same thing as imminent catastrophe, but it is evidence that disease biology is already underway.

What makes the findings notable

Three elements make this study stand out. First is sheer scale. With more than 16,000 participants, REACT is positioned as one of the largest mapping efforts of silent atherosclerosis yet conducted. Second is timing. The results were presented in a major cardiology forum and published simultaneously in the New England Journal of Medicine, signaling that the work is intended to shape mainstream clinical discussion rather than remain a niche observational finding.

Third is the challenge to common assumptions. Public messaging around cardiovascular health often centers on future risk: eat better, exercise more, keep cholesterol in check, avoid smoking, and reduce long-term odds of disease. Those recommendations remain foundational, but REACT suggests the disease process can already be physically present much earlier than many people think. That may eventually support a more disease-detection-oriented prevention strategy rather than one based only on probabilistic risk scoring.

• More than 16,000 apparently healthy adults were included in the REACT study.
• Researchers reported plaques in 57.1% of participants despite no symptoms or prior cardiovascular diagnosis.
• The study suggests silent plaque may already be present in about one in 13 adults before age 30.

The broader question for health systems

The study does not, by itself, answer how health systems should screen for hidden atherosclerosis at scale, which populations should be tested first, or what specific interventions should follow a positive finding. Those are consequential clinical and policy questions. But it does sharpen the case that current prevention models may be catching too many people late in the disease process.

That is likely why the researchers emphasize precision prevention. If silent atherosclerosis can be identified earlier and more directly, clinicians may be better able to distinguish between people who only appear at moderate statistical risk and people who already have measurable arterial disease. For health systems under pressure to prevent costly and deadly cardiovascular events, that distinction could become increasingly important.

For now, REACT’s immediate contribution is conceptual as much as clinical. It reframes atherosclerosis as something that often begins earlier, remains hidden longer, and may deserve earlier attention than many prevention strategies currently provide. The fact that plaques were found in a majority of this symptom-free cohort, and even in some adults under 30, gives that argument unusual force.

If further phases of REACT confirm and extend these findings, the study may help move cardiovascular prevention away from waiting for risk to compound and toward identifying disease while there is still time to alter its course. That would represent a meaningful shift in one of medicine’s most important long-running battles.

This article is based on reporting by Medical Xpress. Read the original article.